Literature DB >> 25520398

Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8+ T cells.

Keisuke Watanabe1, Seitaro Terakura2, Anton C Martens3, Tom van Meerten4, Susumu Uchiyama5, Misa Imai6, Reona Sakemura1, Tatsunori Goto1, Ryo Hanajiri1, Nobuhiko Imahashi1, Kazuyuki Shimada7, Akihiro Tomita1, Hitoshi Kiyoi1, Tetsuya Nishida1, Tomoki Naoe8, Makoto Murata1.   

Abstract

The effectiveness of chimeric Ag receptor (CAR)-transduced T (CAR-T) cells has been attributed to supraphysiological signaling through CARs. Second- and later-generation CARs simultaneously transmit costimulatory signals with CD3ζ signals upon ligation, but may lead to severe adverse effects owing to the recognition of minimal Ag expression outside the target tumor. Currently, the threshold target Ag density for CAR-T cell lysis and further activation, including cytokine production, has not yet been investigated in detail. Therefore, we determined the threshold target Ag density required to induce CAR-T cell responses using novel anti-CD20 CAR-T cells with a CD28 intracellular domain and a CD20-transduced CEM cell model. The newly developed CD20CAR-T cells demonstrated Ag-specific lysis and cytokine secretion, which was a reasonable level as a second-generation CAR. For lytic activity, the threshold Ag density was determined to be ∼200 molecules per target cell, whereas the Ag density required for cytokine production of CAR-T cells was ∼10-fold higher, at a few thousand per target cell. CD20CAR-T cells responded efficiently to CD20-downregulated lymphoma and leukemia targets, including rituximab- or ofatumumab-refractory primary chronic lymphocytic leukemia cells. Despite the potential influence of the structure, localization, and binding affinity of the CAR/Ag, the threshold determined may be used for target Ag selection. An Ag density below the threshold may not result in adverse effects, whereas that above the threshold may be sufficient for practical effectiveness. CD20CAR-T cells also demonstrated significant lytic activity against CD20-downregulated tumor cells and may exhibit effectiveness for CD20-positive lymphoid malignancies.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25520398     DOI: 10.4049/jimmunol.1402346

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  108 in total

1.  Genetically engineered lymphocytes and adoptive cell therapy: cancer immunotherapy's smart bombs.

Authors:  S K Libutti
Journal:  Cancer Gene Ther       Date:  2015-03       Impact factor: 5.987

2.  CD123 CAR T cells for the treatment of myelodysplastic syndrome.

Authors:  Brett M Stevens; Wei Zhang; Daniel A Pollyea; Amanda Winters; Jonathan Gutman; Clayton Smith; Elizabeth Budde; Stephen J Forman; Craig T Jordan; Enkhtsetseg Purev
Journal:  Exp Hematol       Date:  2019-05-25       Impact factor: 3.084

3.  CD19 Chimeric Antigen Receptor T Cells From Patients With Chronic Lymphocytic Leukemia Display an Elevated IFN-γ Production Profile.

Authors:  Isabelle Magalhaes; Ingrid Kalland; James N Kochenderfer; Anders Österborg; Michael Uhlin; Jonas Mattsson
Journal:  J Immunother       Date:  2018 Feb/Mar       Impact factor: 4.456

Review 4.  A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma.

Authors:  Houli Zhao; Yiyun Wang; Elaine Tan Su Yin; Kui Zhao; Yongxian Hu; He Huang
Journal:  Front Med       Date:  2020-12-01       Impact factor: 4.592

5.  Research in morphology and flow cytometry is at the heart of hematology.

Authors:  Marie C Béné; Gina Zini
Journal:  Haematologica       Date:  2017-03       Impact factor: 9.941

Review 6.  Driving CARs on the uneven road of antigen heterogeneity in solid tumors.

Authors:  Nan Chen; Xiaoyu Li; Navin K Chintala; Zachary E Tano; Prasad S Adusumilli
Journal:  Curr Opin Immunol       Date:  2018-03-16       Impact factor: 7.486

7.  CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.

Authors:  Julia Bluhm; Elisa Kieback; Stephen F Marino; Felix Oden; Jörg Westermann; Markus Chmielewski; Hinrich Abken; Wolfgang Uckert; Uta E Höpken; Armin Rehm
Journal:  Mol Ther       Date:  2018-06-18       Impact factor: 11.454

Review 8.  Next-generation regulatory T cell therapy.

Authors:  Leonardo M R Ferreira; Yannick D Muller; Jeffrey A Bluestone; Qizhi Tang
Journal:  Nat Rev Drug Discov       Date:  2019-09-20       Impact factor: 84.694

9.  Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.

Authors:  Gregory A Rufener; Oliver W Press; Philip Olsen; Sang Yun Lee; Michael C Jensen; Ajay K Gopal; Barbara Pender; Lihua E Budde; Jeffrey K Rossow; Damian J Green; David G Maloney; Stanley R Riddell; Brian G Till
Journal:  Cancer Immunol Res       Date:  2016-04-21       Impact factor: 11.151

Review 10.  Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells.

Authors:  William R Strohl; Michael Naso
Journal:  Antibodies (Basel)       Date:  2019-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.